DDInter1620 DDInter1588
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nafcillin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Somapacitan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN10A
SCN10A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurazepam
Flurazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN3A
SCN3A {u} (Gene) is bound by {v} (Compound) Zonisamide
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Ribociclib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) binds SCN3A (Gene) and SCN3A (Gene) is bound by Zonisamide (Compound) and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib